143 related articles for article (PubMed ID: 14735554)
1. Low dose 2-CdA schedule activity in splenic marginal zone lymphomas.
Riccioni R; Caracciolo F; Galimberti S; Cecconi N; Petrini M
Hematol Oncol; 2003 Dec; 21(4):163-8. PubMed ID: 14735554
[TBL] [Abstract][Full Text] [Related]
2. 2-CdA in the treatment of hairy cell leukaemia.
Abhyankar D; Bajpai S; Saikia T; Gopal R; Nair CN; Advani SH
J Assoc Physicians India; 2001 Aug; 49():785-7. PubMed ID: 11837464
[TBL] [Abstract][Full Text] [Related]
3. Deoxycoformycin (pentostatin) in the treatment of splenic marginal zone lymphoma (SMZL) with or without villous lymphocytes.
Iannitto E; Minardi V; Calvaruso G; Ammatuna E; Florena AM; Mulè A; Tripodo C; Quintini G; Abbadessa V
Eur J Haematol; 2005 Aug; 75(2):130-5. PubMed ID: 16000129
[TBL] [Abstract][Full Text] [Related]
4. Treatment of splenic marginal zone lymphoma: splenectomy versus rituximab.
Bennett M; Schechter GP
Semin Hematol; 2010 Apr; 47(2):143-7. PubMed ID: 20350661
[TBL] [Abstract][Full Text] [Related]
5. Hairy cell leukemia: evaluation of the long-term outcome in 121 patients.
Zinzani PL; Pellegrini C; Stefoni V; Derenzini E; Gandolfi L; Broccoli A; Argnani L; Quirini F; Pileri S; Baccarani M
Cancer; 2010 Oct; 116(20):4788-92. PubMed ID: 20597132
[TBL] [Abstract][Full Text] [Related]
6. Splenic lymphoma with villous lymphocytes (SLVL) responding to 2-chlorodeoxyadenosine (2-CdA).
Virchis A; Mehta A
Br J Haematol; 1998 Mar; 100(3):609. PubMed ID: 9504654
[No Abstract] [Full Text] [Related]
7. Significant efficacy of 2-CdA with or without rituximab in the treatment of splenic marginal zone lymphoma (SMZL).
Cervetti G; Galimberti S; Sordi E; Buda G; Orciuolo E; Cecconi N; Petrini M
Ann Oncol; 2010 Apr; 21(4):851-854. PubMed ID: 19825880
[TBL] [Abstract][Full Text] [Related]
8. Applying the new TNM classification system for primary cutaneous lymphomas other than mycosis fungoides and Sézary syndrome in primary cutaneous marginal zone lymphoma.
Gerami P; Wickless SC; Rosen S; Kuzel TM; Ciurea A; Havey J; Guitart J
J Am Acad Dermatol; 2008 Aug; 59(2):245-54. PubMed ID: 18486274
[TBL] [Abstract][Full Text] [Related]
9. 2'-Chlorodeoxyadenosine (2-CdA) as salvage therapy for Langerhans cell histiocytosis (LCH). results of the LCH-S-98 protocol of the Histiocyte Society.
Weitzman S; Braier J; Donadieu J; Egeler RM; Grois N; Ladisch S; Pötschger U; Webb D; Whitlock J; Arceci RJ
Pediatr Blood Cancer; 2009 Dec; 53(7):1271-6. PubMed ID: 19731321
[TBL] [Abstract][Full Text] [Related]
10. Splenic marginal zone lymphoma with or without villous lymphocytes. Hematologic findings and outcomes in a series of 57 patients.
Iannitto E; Ambrosetti A; Ammatuna E; Colosio M; Florena AM; Tripodo C; Minardi V; Calvaruso G; Mitra ME; Pizzolo G; Menestrina F; Franco V
Cancer; 2004 Nov; 101(9):2050-7. PubMed ID: 15389479
[TBL] [Abstract][Full Text] [Related]
11. High-grade transformation in splenic marginal zone lymphoma with circulating villous lymphocytes: the site of transformation influences response to therapy and prognosis.
Dungarwalla M; Appiah-Cubi S; Kulkarni S; Saso R; Wotherspoon A; Osuji N; Swansbury J; Cunningham DC; Catovsky D; Dearden CE; Matutes E
Br J Haematol; 2008 Oct; 143(1):71-4. PubMed ID: 18671706
[TBL] [Abstract][Full Text] [Related]
12. 2-Chlorodeoxyadenosine treatment of low-grade lymphomas.
Kay AC; Saven A; Carrera CJ; Carson DA; Thurston D; Beutler E; Piro LD
J Clin Oncol; 1992 Mar; 10(3):371-7. PubMed ID: 1346801
[TBL] [Abstract][Full Text] [Related]
13. Systemic eight-cycle anti-CD20 monoclonal antibody (rituximab) therapy in primary cutaneous B-cell lymphomas--an applicational observation.
Gellrich S; Muche JM; Wilks A; Jasch KC; Voit C; Fischer T; Audring H; Sterry W
Br J Dermatol; 2005 Jul; 153(1):167-73. PubMed ID: 16029344
[TBL] [Abstract][Full Text] [Related]
14. Outcome and prognostic factors in ocular adnexal lymphoma.
Nola M; Lukenda A; Bollmann M; Kalauz M; Petrovecki M; Bollmann R
Croat Med J; 2004 Jun; 45(3):328-32. PubMed ID: 15185428
[TBL] [Abstract][Full Text] [Related]
15. Significant efficacy of 2-chlorodeoxyadenosine{+/-} rituximab in the treatment of splenic marginal zone lymphoma (SMZL): extended follow-up.
Cervetti G; Galimberti S; Pelosini M; Ghio F; Cecconi N; Petrini M
Ann Oncol; 2013 Sep; 24(9):2434-8. PubMed ID: 23712547
[TBL] [Abstract][Full Text] [Related]
16. Outcomes in splenic marginal zone lymphoma: analysis of 107 patients treated in British Columbia.
Xing KH; Kahlon A; Skinnider BF; Connors JM; Gascoyne RD; Sehn LH; Savage KJ; Slack GW; Shenkier TN; Klasa R; Gerrie AS; Villa D
Br J Haematol; 2015 May; 169(4):520-7. PubMed ID: 25854936
[TBL] [Abstract][Full Text] [Related]
17. Rituximab plus ASHAP for the treatment of patients with relapsed or refractory aggressive non-Hodgkin's lymphoma: a single-centre study of 20 patients.
Aydin S; Dührsen U; Nückel H
Ann Hematol; 2007 Apr; 86(4):271-6. PubMed ID: 17216473
[TBL] [Abstract][Full Text] [Related]
18. A single-center study of treatment outcomes and survival in patients with primary gastric lymphomas between 1990 and 2003.
Jezersek Novaković B; Vovk M; Juznic Setina T
Ann Hematol; 2006 Dec; 85(12):849-56. PubMed ID: 16944146
[TBL] [Abstract][Full Text] [Related]
19. Activity and toxicity of 2-CDA in Langerhans cell histiocytosis: a single institutional experience.
Biswas G; Khadwal A; Arora B; Bhagwat R; Banavali SD; Nair CN; Pai SK; Kurkure PA; Parikh PM
Indian J Cancer; 2007; 44(4):137-41. PubMed ID: 18322355
[TBL] [Abstract][Full Text] [Related]
20. [Splenic marginal zone B-cell lymphoma with bilateral renal invasion after splenectomy].
Hoshino T; Iriuchijima H; Ogawa Y; Irisawa H; Jinbo T
Rinsho Ketsueki; 2008 Jan; 49(1):35-9. PubMed ID: 18277594
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
